Watson's Opana ANDA Triggers Endo, Penwest Suit

Law360, New York (March 9, 2010, 3:32 PM EST) -- Watson Pharmaceuticals Inc. has revealed that it is facing a patent infringement suit from Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. following the generics maker's bid for approval of its own version of painkiller Opana ER.

Watson announced Monday that subsidiary Watson Laboratories Inc. had been sued by Endo and Penwest in connection with an abbreviated new drug application asking the U.S. Food and Drug Administration to approve 40 mg oxymorphone hydrochloride extended release tablets, a generic version of Opana.

In January, Watson alerted Endo and...
To view the full article, register now.